MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non ...
MAIA Biotechnology reports favorable interim survival benefit for THIO in advanced NSCLC, with 16 patients surpassing 12-month follow-up, including 9 in third-line treatment achieving a median survival of 10.6 months, surpassing standard-of-care overall survival of 5.8 months. THIO followed by Libtayo® has been well-tolerated.
Related Clinical Trials
Highlighted Terms
Related News
MAIA Biotechnology reports positive survival updates in Phase 2 THIO study for NSCLC, with 16 patients surpassing 12-month follow-up, and median survival in third line at 10.6 months, exceeding standard-of-care's 5.8 months.
THIO-101 trial data shows potential OS benefit in advanced NSCLC patients treated with THIO and cemiplimab after 2+ SOC regimens, with 16 patients surpassing 12 months OS, including 9 in the third-line setting (median OS 10.6 months). MAIA Biotechnology notes that THIO's survival benefit supports its potential as a treatment option for advanced NSCLC.
MAIA Biotechnology reports favorable interim survival benefit for THIO in advanced NSCLC, with 16 patients surpassing 12-month follow-up, including 9 in third-line treatment achieving a median survival of 10.6 months, surpassing standard-of-care overall survival of 5.8 months. THIO followed by Libtayo® has been well-tolerated.
Combining THIO with cemiplimab showed a survival benefit in advanced NSCLC patients, with a median survival of 10.6 months in third-line therapy. THIO-101 trial interim results also revealed an 85% disease control rate and 38% overall response rate. Full efficacy results are expected later this year.
16 patients surpassed 12-month survival follow-up, with THIO's substantial survival benefit in third line surpassing standard-of-care overall survival of 5.8 months, with a median survival follow-up of 10.6 months. Treatment with THIO followed by Libtayo® has been generally well-tolerated.
MAIA Biotechnology Inc. reported positive interim survival benefits in a phase 2 study of THIO, its lead therapy for advanced non-small cell lung cancer (NSCLC). THIO-101 trial results show 12-month survival follow-ups surpassing 12 months, with interim median survival in third-line patients at 10.6 months. THIO targets telomeres, key in cancer cell survival and spread, and has shown favorable disease control and overall response rates, with plans to expand its use to other cancer types.
MAIA Biotechnology announces 16 NSCLC patients surpassed 12-month survival with THIO, showing 10.6-month median survival in third-line treatment, surpassing standard-of-care's 5.8 months.
MAIA Biotechnology Inc. reports encouraging interim results from phase 2 THIO-101 trial for advanced NSCLC, showing survival benefits with 16 patients exceeding 12 months follow-up. THIO targets telomeres to induce DNA damage and cancer cell death, with plans to explore its use in other cancers like HCC, SCLC, and malignant gliomas.